Phase 2 Thyroid Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have given written consent approved by an ethics committee
• You are 18 years of age or older
• You have been confirmed by tissue testing to have either: advanced or spreading differentiated thyroid cancer that no longer responds to radioactive iodine treatment (Group A), or anaplastic thyroid cancer (Group B)
• Group A: Your cancer got worse after trying at least one approved drug (Sorafenib, Lenvatinib, or Cabozantinib), and you have had no more than 3 prior drug treatments total
• Group B: You are either starting your first treatment, or you have tried no more than one previous drug treatment
• Your cancer can be seen and measured on scans
• A stored tissue sample from your tumour is available, or you are able to provide a new biopsy sample
• You are generally well enough to carry out light activity and care for yourself (confirm with trial site)
• Your blood counts, liver, kidney, and other lab results meet certain minimum health levels (confirm with trial site)
• If you are a woman who could become pregnant: you agree not to try to get pregnant during the study and for at least 6 months after finishing treatment, have a negative pregnancy test within 7 days before starting, and agree to use effective contraception throughout
• If you are a woman who cannot become pregnant: you are postmenopausal (no periods for at least 1 year) or have had a surgical procedure that prevents pregnancy
• You agree not to breastfeed or donate eggs during the study and for at least 6 months after finishing treatment (if applicable)
• If you are a man: you agree not to donate sperm during the study and for at least 6 months after finishing treatment
• If you are a man whose partner could become pregnant, is pregnant, or is breastfeeding: you agree to use a condom and an additional form of effective contraception during the study and for at least 6 months after finishing treatment
• You agree not to join another treatment-based clinical trial while taking part in this study

Who may not be able to join:

• Your cancer has spread to the brain or central nervous system
• You are still experiencing significant side effects (moderate or severe) from a previous cancer treatment, including surgery, radiation, or drug therapy
• You have had another cancer in the past 3 years, or still have signs of a previous cancer (exceptions may apply for certain skin cancers, fully treated prostate cancer, or fully removed non-invasive cancers — confirm with trial site)
• You have active Hepatitis B, active Hepatitis C, or HIV
• You have HIV with a detectable level of virus in your blood, or you take medications that may interfere with how the study drug works
• You have had a stroke or mini-stroke, or have had a serious heart event such as a heart attack or unstable chest pain within the last 6 months
• You have a history of serious heart rhythm problems or significant heart failure (confirm with trial site)
• You have a significant ongoing lung condition such as severe COPD or another moderate-to-severe breathing illness in the past 6 months
• You have active inflammatory bowel disease (such as ulcerative colitis or Crohn's disease), or have had a bowel blockage or tear in the past 6 months
• Your high blood pressure or diabetes is not well controlled
• You have had major surgery or radiation therapy within the past 4 weeks
• You have received a live vaccine in the past 30 days, or antibiotics in the past week
• You have received chemotherapy, immunotherapy, or other cancer drug treatments within the past 2 weeks
• You have previously been treated with a type of drug called a topoisomerase 1 inhibitor (confirm with trial site)
• You have a known allergy to the study drug (sacituzumab govitecan) or any of its ingredients
• You have other health conditions that your doctor feels would make it unsafe for you to receive or tolerate the treatment

Important: Always verify eligibility with the trial site directly before applying.